High-dose methotrexate in the mobilization of hematopoietic stem cells for patients with non-Hodgkin's lymphoma: a twelve-year study in a single center

Background High‐dose chemotherapy followed by autologous hematopoietic stem cell transplantation (auto‐HSCT) is a promising approach for non‐Hodgkin's lymphoma (NHL). Higher cell doses have been associated with a faster blood count recovery and a reduction in transfusion requirements, infection...

Full description

Saved in:
Bibliographic Details
Published in:Transfusion (Philadelphia, Pa.) Pa.), 2014-05, Vol.54 (5), p.1251-1255
Main Authors: Zhang, Cheng, Chen, Xing-Hua, Gao, Li, Liu, Yao, Gao, Lei, Kong, Pei-Yan, Zeng, Dong-Feng, Peng, Xian-Gui, Sun, Ai-Hua, Zhang, Xi
Format: Article
Language:English
Subjects:
Adolescent
Adult
Aged
Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy
Biological and medical sciences
Blood. Blood and plasma substitutes. Blood products. Blood cells. Blood typing. Plasmapheresis. Apheresis
Female
Hematologic and hematopoietic diseases
Hematopoiesis
Hematopoietic Stem Cell Mobilization - adverse effects
Humans
Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis
Lymphoma, Non-Hodgkin - blood
Lymphoma, Non-Hodgkin - therapy
Male
Medical sciences
Methotrexate - pharmacology
Middle Aged
Receptors, CXCR4 - physiology
Transfusions. Complications. Transfusion reactions. Cell and gene therapy
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background High‐dose chemotherapy followed by autologous hematopoietic stem cell transplantation (auto‐HSCT) is a promising approach for non‐Hodgkin's lymphoma (NHL). Higher cell doses have been associated with a faster blood count recovery and a reduction in transfusion requirements, infection rates, and hospitalization times. Mobilization failure constitutes one of the main reasons for avoiding auto‐HSCT. The role of high‐dose methotrexate (MTX) as mobilization regimen is still unclear. Study Design and Methods The effect of high‐dose MTX as a mobilization regimen for 67 adult patients with NHL who received auto‐HSCT was studied between January 2001 and October 2012. The stem cells were mobilized using combination chemotherapy including MTX plus granulocyte–colony‐stimulating factor (G‐CSF) in 33 patients (Group A), and the stem cells of the other 34 patients were mobilized using the same combination chemotherapy plus G‐CSF without MTX (Group B). Results All of the patients were successfully mobilized in Group A; however, two patients failed in Group B. The median numbers of CD34+ cells collected were 14.36 × 106 and 5.3 × 106 cells/kg for Groups A and B, respectively (p 
ISSN:0041-1132
1537-2995
DOI:10.1111/trf.12516